<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Allaw AB</submitter><funding>NHLBI NIH HHS</funding><pagination>529-537</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11385397</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>5(8)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The benefit of pulmonary vein isolation (PVI) in patients with atrial fibrillation (AF) and heart failure with reduced ejection fraction (HFrEF) is well established; its efficacy in patients with heart failure preserved ejection fraction (HFpEF) is less clear.&lt;h4>Objective&lt;/h4>The objective of the study was to compare AF and heart failure (HF) rehospitalizations after PVI in patients with HFpEF vs HFrEF.&lt;h4>Methods&lt;/h4>The IBM MarketScan Database was used to identify patients undergoing PVI for AF. Patients were categorized by HF status: absence of HF, presence of HFrEF, or presence of HFpEF. Primary outcomes were HF and arrhythmia hospitalizations after PVI.&lt;h4>Results&lt;/h4>A total of 32,524 patients were analyzed: 27,900 with no HF (86%), 2948 with HFrEF (9%), and 1676 with HFpEF (5%). Compared with those with no HF, both patients with HFrEF and HFpEF were more likely to be hospitalized for HF (hazard ratio [HR] 7.27; &lt;i>P&lt;/i> &lt; .01 for HFrEF and HR 9.46; &lt;i>P&lt;/i> &lt; .01 for HFpEF) and for AF (HR 1.17; &lt;i>P&lt;/i> &lt; .01 for HFrEF and HR 1.74; &lt;i>P&lt;/i> &lt; .01 for HFpEF) after PVI. In matched analysis, 23% of patients with HFrEF and 24% patients with HFpEF demonstrated a reduction in HF hospitalizations (&lt;i>P&lt;/i> = .31) and approximately one-third demonstrated decreased arrhythmia rehospitalizations (&lt;i>P&lt;/i> = .57) in the 6 months after PVI. Compared with those with HFrEF in longer-term follow-up (>1 year), patients with HFpEF were more likely to have HF (HR 1.30; &lt;i>P&lt;/i> &lt; .01) and arrhythmia (HR 1.19; &lt;i>P&lt;/i> &lt; .01) rehospitalizations.&lt;h4>Conclusion&lt;/h4>Reductions in HF and arrhythmia hospitalizations are observed early after PVI across all patients with HF, but patients with HFpEF demonstrate higher HF rehospitalization and arrhythmia recurrence in longer-term follow-up than do patients with HFrEF.</pubmed_abstract><journal>Heart rhythm O2</journal><pubmed_title>Comparing outcomes after pulmonary vein isolation in patients with systolic and diastolic heart failure.</pubmed_title><pmcid>PMC11385397</pmcid><funding_grant_id>T32 HL007381</funding_grant_id><pubmed_authors>Gampa A</pubmed_authors><pubmed_authors>Rao S</pubmed_authors><pubmed_authors>Guo J</pubmed_authors><pubmed_authors>Ozcan C</pubmed_authors><pubmed_authors>Besser SA</pubmed_authors><pubmed_authors>Yeshwant S</pubmed_authors><pubmed_authors>Upadhyay GA</pubmed_authors><pubmed_authors>Roy D</pubmed_authors><pubmed_authors>Aziz Z</pubmed_authors><pubmed_authors>Beaser AD</pubmed_authors><pubmed_authors>Treger J</pubmed_authors><pubmed_authors>Allaw AB</pubmed_authors></additional><is_claimable>false</is_claimable><name>Comparing outcomes after pulmonary vein isolation in patients with systolic and diastolic heart failure.</name><description>&lt;h4>Background&lt;/h4>The benefit of pulmonary vein isolation (PVI) in patients with atrial fibrillation (AF) and heart failure with reduced ejection fraction (HFrEF) is well established; its efficacy in patients with heart failure preserved ejection fraction (HFpEF) is less clear.&lt;h4>Objective&lt;/h4>The objective of the study was to compare AF and heart failure (HF) rehospitalizations after PVI in patients with HFpEF vs HFrEF.&lt;h4>Methods&lt;/h4>The IBM MarketScan Database was used to identify patients undergoing PVI for AF. Patients were categorized by HF status: absence of HF, presence of HFrEF, or presence of HFpEF. Primary outcomes were HF and arrhythmia hospitalizations after PVI.&lt;h4>Results&lt;/h4>A total of 32,524 patients were analyzed: 27,900 with no HF (86%), 2948 with HFrEF (9%), and 1676 with HFpEF (5%). Compared with those with no HF, both patients with HFrEF and HFpEF were more likely to be hospitalized for HF (hazard ratio [HR] 7.27; &lt;i>P&lt;/i> &lt; .01 for HFrEF and HR 9.46; &lt;i>P&lt;/i> &lt; .01 for HFpEF) and for AF (HR 1.17; &lt;i>P&lt;/i> &lt; .01 for HFrEF and HR 1.74; &lt;i>P&lt;/i> &lt; .01 for HFpEF) after PVI. In matched analysis, 23% of patients with HFrEF and 24% patients with HFpEF demonstrated a reduction in HF hospitalizations (&lt;i>P&lt;/i> = .31) and approximately one-third demonstrated decreased arrhythmia rehospitalizations (&lt;i>P&lt;/i> = .57) in the 6 months after PVI. Compared with those with HFrEF in longer-term follow-up (>1 year), patients with HFpEF were more likely to have HF (HR 1.30; &lt;i>P&lt;/i> &lt; .01) and arrhythmia (HR 1.19; &lt;i>P&lt;/i> &lt; .01) rehospitalizations.&lt;h4>Conclusion&lt;/h4>Reductions in HF and arrhythmia hospitalizations are observed early after PVI across all patients with HF, but patients with HFpEF demonstrate higher HF rehospitalization and arrhythmia recurrence in longer-term follow-up than do patients with HFrEF.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Aug</publication><modification>2025-04-04T09:49:05.995Z</modification><creation>2025-04-04T09:49:05.995Z</creation></dates><accession>S-EPMC11385397</accession><cross_references><pubmed>39263616</pubmed><doi>10.1016/j.hroo.2024.07.003</doi></cross_references></HashMap>